Bedrocan launches new cannabis product with high CBD content

Bedrocan is going to commercialise a new cannabis variety with a cannabidiol (CBD) content of 14 per cent. With this, we are  responding to increasing demand for medicinal cannabis with high CBD content. The new variety will be produced primarily at the new facility in Denmark. “The new CBD variety will be available under the brand name Bedrolina®”, CEO Jaap Erkelens reveals.

There is a lot of demand for CBD with high CBD levels. Drug developers usually process the CBD in cannabis into medicinal oils or ointments. Erkelens continues: “Hemp varieties, which are grown in the open field worldwide, often contain a lower CBD percentage, which means that more biomass is needed. In addition, these hemp varieties are not suitable for pharmaceutical applications. Bedrolina®, on the other hand, is grown and packaged entirely under GMCCP / GMP and is free of pesticides and other contaminants.”

Production facility in Denmark

The brand new production facility in Denmark will be operational in Q1, 2025. Erkelens about this project: “The construction took about a year and a half, but we got exactly what we wanted. Everything was set up according to Bedrocan’s method so we can also supply standardised medicinal cannabis from this facility. The advantage of working from Denmark is the possibility to do business without the direct intervention of a government organisation such as in the Netherlands.”

Growing outdoors

Bedrocan also plans to grow Bedrolina® on a large scale outdoors. This is unique because Bedrocan currently only grows indoors. With the outdoor biomass, Bedrocan is targeting primarily the cosmetics industry. The demand for CBD has grown substantially, partially due to the inclusion of naturally-derived cannabidiol in the Cosing (Common cosmetic ingredient ) database that lists all substances authorised in cosmetics.